biphenyl-3,4-diamine | 4458-39-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: biphenyl-3,4-diamine
• 英文别名: [1,1'-biphenyl]-3,4-diamine；5-phenyl-1,2-phenylenediamine；4-phenylbenzene-1,2-diamine
• CAS: 4458-39-3
• 化学式: C₁₂H₁₂N₂
• 分子量: 184.241
• InChiKey: KYEFUIBOKLKQPD-UHFFFAOYSA-N

物化性质

• 熔点：
  102-103 °C
• 沸点：
  371.4±30.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090

反应信息

• 作为反应物：
  描述：

  biphenyl-3,4-diamine 在 盐酸羟胺 、 溶剂黄146 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 N-hydroxy-7-(5-phenyl-1H-benzo[d]imidazol-2-yl)heptanamide
  参考文献：
  名称：

  Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents

  摘要：

  A series of benzimidazole based HDAC inhibitors have been rationally designed, synthesized and screened. The SAR of this new chemotype is described. The lead compound, 11e, showed strong activity in several cellular assays and demonstrated in vivo efficacy in mouse xenograft pancreatic cancer models. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.001
• 作为产物：
  描述：

  5-溴-2-硝基苯胺 在 四(三苯基膦)钯 、 palladium on activated charcoal 、 甲酸铵 、 potassium carbonate 作用下， 生成 biphenyl-3,4-diamine
  参考文献：
  名称：

  Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents

  摘要：

  A series of benzimidazole based HDAC inhibitors have been rationally designed, synthesized and screened. The SAR of this new chemotype is described. The lead compound, 11e, showed strong activity in several cellular assays and demonstrated in vivo efficacy in mouse xenograft pancreatic cancer models. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.001
• 作为试剂：
  描述：

  (3'-chloro-3-nitro-biphenyl-4-yl)-(1-pyrimidin-2-yl-piperidin-4-yl)-amine 在 钯 氢气 、 N4-(1-pyrimidin-2-yl)piperidin-4-yl 、 biphenyl-3,4-diamine 作用下， 以 乙醇 为溶剂， 反应 2.06h， 以to give 196 mg (69%) of 3′-chloro-N4-(1-(pyrimidin-2-yl)piperidin-4-yl)biphenyl-3,4-diamine [LC-MS [M+1]=380.0 (doublet); HPLC=2.02 min.] and 42 mg (16%) of N4-(1-pyrimidin-2-yl)piperidin-4-yl)biphenyl-3,4-diamine [LC-MS [M+1]=346.1; HPLC=1.85 min.]的产率得到3'-chloro-N4-(1-(pyrimidin-2-yl)piperidin-4-yl)biphenyl-3,4-diamine
  参考文献：
  名称：

  Amine-linked Multicyclic Compounds and Methods of Their Use

  摘要：

  本发明涉及多环化合物、包含它们的药物组合物以及它们的使用方法。本发明的特定化合物为公式I:

  公开号：

  US20080139598A1

文献信息

• Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity Relationships
  作者：Paul S. Charifson、Anne-Laure Grillot、Trudy H. Grossman、Jonathan D. Parsons、Michael Badia、Steve Bellon、David D. Deininger、Joseph E. Drumm、Christian H. Gross、Arnaud LeTiran、Yusheng Liao、Nagraj Mani、David P. Nicolau、Emanuele Perola、Steven Ronkin、Dean Shannon、Lora L. Swenson、Qing Tang、Pamela R. Tessier、Ski-Kai Tian、Martin Trudeau、Tiansheng Wang、Yunyi Wei、Hong Zhang、Dean Stamos

  DOI：10.1021/jm800318d

  日期：2008.9.11

  hospital- and community-acquired infections. The discovery and optimization of this novel class of antibacterials by the use of structure-guided design, modeling, and structure-activity relationships are described. Data are presented for enzyme inhibition, antibacterial activity, and in vivo efficacy by oral and intravenous administration in two rodent infection models.

  为了克服影响所有目前使用的抗生素种类的细菌耐药性问题，发现具有新颖作用机制的新型抗菌剂是必要的。细菌DNA促旋酶和拓扑异构酶IV是氟喹诺酮类抗生素的特征明确的临床验证靶标，它们通过抑制催化亚基发挥其抗菌活性。通过与它们的ATP位点相互作用来抑制这些靶标在临床上不太成功。提出了一种新型的低分子量，与ATP位点结合的回旋酶和拓扑异构酶IV合成抑制剂的发现和表征。苯并咪唑脲是两种酶的双重靶向抑制剂，并且对引起医院和社区获得性感染的各种相关病原体具有有效的抗菌活性。描述了通过使用结构指导的设计，建模和结构-活性关系来发现和优化这种新型抗菌剂。提供了在两种啮齿动物感染模型中通过口服和静脉内给药的酶抑制，抗菌活性和体内功效的数据。
• Spirocyclic compounds
  申请人：Berk C. Scott

  公开号：US20070117824A1

  公开（公告）日：2007-05-24

  The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型的取代螺环化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于在选择性诱导终末分化、阻止肿瘤细胞生长和/或凋亡的过程中使用，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤特征的患者方面是有用的，这些肿瘤具有肿瘤细胞的增殖。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用，例如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供了包括本发明化合物的药物组合物和这些药物组合物的安全用药方案，这些方案易于遵循，并在体内产生这些化合物的治疗有效量。
• One-step approach for the synthesis of functionalized quinoxalines mediated by T3P®–DMSO or T3P® via a tandem oxidation–condensation or condensation reaction
  作者：Kachigere B. Harsha、Kanchugarkoppal S. Rangappa

  DOI：10.1039/c6ra03078e

  日期：——

  An easy and efficient propylphosphonic anhydride (T3P®)–DMSO or T3P® mediated oxidation–condensation or condensation reaction for the synthesis of quinoxalines derived from the interaction of different arrays of condensing partners with ortho-phenylene diamines (o-PDs) under simple and mild reaction conditions in one step has been reported for the first time.

  一种简单有效的丙基膦酸酐（T3P®）-DMSO或T3P®介导的氧化-缩合或缩合反应，用于合成喹喔啉，该喹喔啉是在简单和简单的条件下衍生自不同阵列的缩合配偶与邻苯二胺（o -PDs）相互作用的产物。首次报道温和的反应条件。
• Synthesis of Structurally Diverse Benzotriazoles via Rapid Diazotization and Intramolecular Cyclization of 1,2‐Aryldiamines
  作者：Réka J. Faggyas、Nikki L. Sloan、Ned Buijs、Andrew Sutherland

  DOI：10.1002/ejoc.201900463

  日期：2019.9

  mild conditions, using a polymer‐supported nitrite reagent and p‐tosic acid. The functional group tolerance of this approach was further demonstrated with effective activation and cyclization of N‐alkyl, ‐aryl, and ‐acyl ortho‐aminoanilines leading to the synthesis of N1‐substituted benzotriazoles. The synthetic utility of this one‐pot heterocyclization process was exemplified with the preparation of a

  已经开发了一种操作简单的方法，通过使用聚合物负载的亚硝酸盐试剂和对甲苯磺酸在温和条件下通过重氮化和分子内环化多种 1,2-芳基二胺来制备 N-未取代的苯并三唑。通过有效活化和环化 N-烷基、-芳基和-酰基邻-氨基苯胺，合成 N1 取代的苯并三唑，进一步证明了该方法的官能团耐受性。这种单锅杂环化过程的合成效用可以通过制备许多具有生物学和医学意义的苯并三唑支架来举例说明，包括一种 α-氨基酸类似物。
• 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS
  申请人：MISSION THERAPEUTICS LIMITED

  公开号：US20200331888A1

  公开（公告）日：2020-10-22

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R 1a , R 1b , R 1c , R 1d , R 1e and R 1f each independently represent hydrogen, optionally substituted C 1 -C 6 alkyl or optionally substituted C 3 -C 4 cycloalkyl, or R 1b and R 1c together form an optionally substituted C 3 -C 6 cycloalkyl ring, or R 1d and R 1e together form an optionally substituted C 3 -C 6 cycloalkyl ring; R 2 represents hydrogen or optionally substituted C 1 -C 6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

  本发明涉及新化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C-末端水解酶30或泛素特异性肽酶30（USP30）。这些新化合物的化学式为（I）：（化学式（I）），或其药学上可接受的盐，其中：R1a，R1b，R1c，R1d，R1e和R1f分别独立地代表氢，可选择地取代的C1-C6烷基或可选择地取代的C3-C4环烷基，或者R1b和R1c共同形成一个可选择地取代的C3-C6环烷基环，或者R1d和R1e共同形成一个可选择地取代的C3-C6环烷基环；R2代表氢或可选择地取代的C1-C6烷基；A代表一个可选择地进一步取代的5到10个成员的单环或双环杂环芳基，杂环烷基或芳基环；L代表一个共价键或连接物；B代表一个可选择地取代的3到10个成员的单环或双环杂环烷基，杂环芳基，环烷基或芳基环；当-A-L-B位于位置x时，通过A的一个碳环原子连接到A，且：A不能是三唑吡啶基，三唑吡啉基，咪唑三嗪基，咪唑吡嗪基或吡咯嘧啶基；或者B不能被苯氧基取代；或者当L是氧原子时，B不能是环戊基。